Nanotechnology Applications in Breast Cancer Immunotherapy
Small · 21.12.2023
DOI: 10.1002/smll.202308639 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 21.12.2023. Verfasst von Ruijie Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Oregon Health & Science University, 3303 S Bond Ave, Portland, OR, 97239, USA. Hauptthemen laut MEDLINE: Immunotherapy, Breast Neoplasms, Nanotechnology. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 287 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Kuni Foundation, National Cancer Institute.
Abstract (Originalsprache)
Next‐generation cancer treatments are expected not only to target cancer cells but also to simultaneously train immune cells to combat cancer while modulating the immune‐suppressive environment of tumors and hosts to ensure a robust and lasting response. Achieving this requires carriers that can codeliver multiple therapeutics to the right cancer and/or immune cells while ensuring patient safety. Nanotechnology holds great potential for addressing these challenges. This article highlights the recent advances in nanoimmunotherapeutic development, with a focus on breast cancer. While immune checkpoint inhibitors (ICIs) have achieved remarkable success and lead to cures in some cancers, their response rate in breast cancer is low. The poor response rate in solid tumors is often associated with the low infiltration of anti‐cancer T cells and an immunosuppressive tumor microenvironment (TME). To enhance anti‐cancer T‐cell responses, nanoparticles are employed to deliver ICIs, bispecific antibodies, cytokines, and agents that induce immunogenic cancer cell death (ICD). Additionally, nanoparticles are used to manipulate various components of the TME, such as immunosuppressive myeloid cells, macrophages, dendritic cells, and fibroblasts to improve T‐cell activities. Finally, this article discusses the outlook, challenges, and future directions of nanoimmunotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Oregon Health & Science University, 3303 S Bond Ave, Portland, OR, 97239, USA.
- PDX Pharmaceuticals, 3303 S Bond Ave, CH13B, Portland, OR, 97239, USA.
ORCID-Profile: Worapol Ngamcherdtrakul, Wassana Yantasee
Förderung
- NCI NIH HHS
- Kuni Foundation
- National Cancer Institute
Zitieren
APA
Wang, R., Kumar, P., Reda, M., Wallstrum, A. G., Crumrine, N. A., Ngamcherdtrakul, W., & Yantasee, W. (2023). Nanotechnology Applications in Breast Cancer Immunotherapy. Small. https://doi.org/10.1002/smll.202308639
Vancouver
Wang R, Kumar P, Reda M, Wallstrum AG, Crumrine NA, Ngamcherdtrakul W, et al. Nanotechnology Applications in Breast Cancer Immunotherapy. Small. 2023. doi:10.1002/smll.202308639
BibTeX
@article{Wang2023,
author = {Wang, Ruijie and Kumar, Pramod and Reda, Moataz and Wallstrum, Alyssa G and Crumrine, Noah A and Ngamcherdtrakul, Worapol and Yantasee, Wassana},
title = {Nanotechnology Applications in Breast Cancer Immunotherapy},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202308639}
}
EUVIMED